Trial Profile

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naive Patients Starting Raltegravir Plus Tenofovir/Emtricitabine.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms MARAVIBOOST

Most Recent Events

23 Jun 2012 New source identified and integrated (European Clinical Trials Database).
23 Jun 2012 Status changed from active, no longer recruiting to completed, according to the European Clinical Trials Database.
08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com